These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 12877061)
1. [Pharmacology of anxiolytics and their therapeutic use]. Tada K Ryoikibetsu Shokogun Shirizu; 2003; (38):608-11. PubMed ID: 12877061 [No Abstract] [Full Text] [Related]
2. Pharmacology of the serotonergic anxiolytic tandospirone (SM-3997). Seymour PA; Mena EE; McLean S; Heym J Prog Clin Biol Res; 1990; 361():453-60. PubMed ID: 1981263 [No Abstract] [Full Text] [Related]
3. Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link. Stahl SM J Clin Psychiatry; 1997; 58 Suppl 8():20-6. PubMed ID: 9236732 [TBL] [Abstract][Full Text] [Related]
4. Buspirone and related compounds as alternative anxiolytics. Taylor DP; Moon SL Neuropeptides; 1991 Jul; 19 Suppl():15-9. PubMed ID: 1679210 [TBL] [Abstract][Full Text] [Related]
5. [The mechanisms of the anxiolytic action of 1-(2-pyrimidinyl)-piperazine derivatives, serotonin agonists]. Talalaenko AN; Kharin NA Eksp Klin Farmakol; 1993; 56(2):11-3. PubMed ID: 8102289 [TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease. Takei A; Honma S; Kawashima A; Yabe I; Fukazawa T; Hamada K; Hamada T; Tashiro K Psychiatry Clin Neurosci; 2002 Apr; 56(2):181-5. PubMed ID: 11952922 [TBL] [Abstract][Full Text] [Related]
8. Effect of serotonin 1A agonist tandospirone on depression symptoms in senile patients with dementia. Masuda Y; Akagawa Y; Hishikawa Y Hum Psychopharmacol; 2002 Jun; 17(4):191-3. PubMed ID: 12404687 [TBL] [Abstract][Full Text] [Related]
9. Effects of tandospirone, a serotonin-1A agonist, on the hypothalamo-pituitary-gonadal axis of male patients. Kaneda Y; Fujii A Neuro Endocrinol Lett; 2001 Aug; 22(4):243-7. PubMed ID: 11524630 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment of blepharospasm with tandospirone, a 5-HT1A partial agonist: a case report. Takahashi T; Murata T; Wada Y Mov Disord; 2008 Jan; 23(1):151-2. PubMed ID: 17987656 [No Abstract] [Full Text] [Related]
11. Use of a serotonin 1A receptor agonist to treat restless legs syndrome. Shioda K; Nisijima K; Yamauchi Y; Ohtuka K; Kato S J Clin Psychopharmacol; 2006 Dec; 26(6):673-5. PubMed ID: 17110833 [No Abstract] [Full Text] [Related]
12. [The different mechanism of the inhibition by buspirone and its camphorimide analogs of 5-HT3-serotoninergic effects]. Kharin NA; Abramets II; Komissarov IV; Samoĭlovich IM Biull Eksp Biol Med; 1993 Aug; 116(8):167-9. PubMed ID: 7903873 [TBL] [Abstract][Full Text] [Related]
13. The use and development of anxiolytics in Japan. Yamawaki S Eur Neuropsychopharmacol; 1999 Dec; 9 Suppl 6():S413-9. PubMed ID: 10622688 [TBL] [Abstract][Full Text] [Related]
14. Early response and 8-week treatment outcome in GAD. Rynn M; Khalid-Khan S; Garcia-Espana JF; Etemad B; Rickels K Depress Anxiety; 2006; 23(8):461-5. PubMed ID: 16845651 [TBL] [Abstract][Full Text] [Related]